These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33093581)

  • 21. Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China.
    Lan B; Abudureheiyimu N; Zhang J; Wang C; Jiang S; Wang J; Ma F; Luo Y; Chen S; Xu B; Fan Y
    Int J Cancer; 2020 Dec; 147(11):3199-3205. PubMed ID: 32535918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.
    Pons-Tostivint E; Kirova Y; Lusque A; Campone M; Geffrelot J; Mazouni C; Mailliez A; Pasquier D; Madranges N; Firmin N; Crouzet A; Gonçalves A; Jankowski C; De La Motte Rouge T; Pouget N; de La Lande B; Mouttet-Boizat D; Ferrero JM; Uwer L; Eymard JC; Mouret-Reynier MA; Petit T; Robain M; Filleron T; Cailliot C; Dalenc F
    Ann Surg Oncol; 2019 Feb; 26(2):356-365. PubMed ID: 30539492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
    Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
    Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
    Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients.
    Lin Y; Yin W; Yan T; Zhou L; Di G; Wu J; Shen Z; Shao Z; Lu J
    BMC Cancer; 2009 Sep; 9():342. PubMed ID: 19778431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
    Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study.
    Chen W; Huang Y; Lewis GD; Szeja SS; Hatch SS; Farach A; Miltenburg D; Butler EB; Chang JC; Teh BS
    Clin Breast Cancer; 2018 Feb; 18(1):e97-e105. PubMed ID: 28888581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy.
    Wu SG; He ZY; Li FY; Wang JJ; Guo J; Lin Q; Guan XX
    Chin J Cancer; 2010 Jul; 29(7):668-76. PubMed ID: 20591219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
    Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
    Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
    Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
    Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.
    Soran A; Ozmen V; Ozbas S; Karanlik H; Muslumanoglu M; Igci A; Canturk Z; Utkan Z; Ozaslan C; Evrensel T; Uras C; Aksaz E; Soyder A; Ugurlu U; Col C; Cabioglu N; Bozkurt B; Uzunkoy A; Koksal N; Gulluoglu BM; Unal B; Atalay C; Yıldırım E; Erdem E; Salimoglu S; Sezer A; Koyuncu A; Gurleyik G; Alagol H; Ulufi N; Berberoglu U; Dulger M; Cengiz O; Sezgin E; Johnson R
    Ann Surg Oncol; 2018 Oct; 25(11):3141-3149. PubMed ID: 29777404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
    Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
    Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective.
    Choi SH; Kim JW; Choi J; Sohn J; Kim SI; Park S; Park HS; Jeong J; Suh CO; Keum KC; Kim YB; Lee IJ
    Clin Breast Cancer; 2018 Apr; 18(2):e167-e178. PubMed ID: 28689012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.